Kbc Group Nv Coherus Bio Sciences, Inc. Transaction History

Kbc Group Nv

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Feb 15, 2024	SELL	$3.74 - $5.45 $2,853 - $4,158	-763 Reduced 13.88%	4,736 $18,000
Q3 2022 Feb 15, 2024	BUY	$7.17 - $13.87 $39,427 - $76,271	5,499 New	5,499 $53,000
Q2 2022 Feb 14, 2024	SELL	$5.86 - $13.23 $175,389 - $395,973	-29,930 Reduced 84.48%	5,499 $40,000
Q2 2022 Jul 26, 2022	BUY	$5.86 - $13.23 $32,224 - $72,751	5,499 New	5,499 $40,000
Q1 2022 May 06, 2022	SELL	$10.92 - $16.41 $386,884 - $581,389	-35,429 Closed	0 $0
Q4 2021 Feb 14, 2024	BUY	$15.81 - $18.99 $560,132 - $672,796	35,429 New	35,429 $565,000
Q4 2021 Feb 03, 2022	SELL	$15.81 - $18.99 $24,047 - $28,883	-1,521 Reduced 4.12%	35,429 $565,000
Q3 2021 Nov 10, 2021	SELL	$12.68 - $17.79 $5,236 - $7,347	-413 Reduced 1.11%	36,950 $594,000
Q2 2021 Aug 11, 2021	BUY	$12.95 - $15.41 $68,596 - $81,626	5,297 Added 16.52%	37,363 $517,000
Q1 2021 Apr 26, 2021	BUY	$14.42 - $21.39 $462,391 - $685,891	32,066 New	32,066 $468,000
Q4 2020 Feb 10, 2021	SELL	$16.56 - $18.94 $506,471 - $579,260	-30,584 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$14.43 - $19.16 $441,327 - $585,989	30,584 New	30,584 $546,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.